REG - Ergomed plc - Block Listing Application

ErgomedAnnouncement

19/12/2019 12:00

RNS Number : 5133X
Ergomed plc
19 December 2019
 


Block Listing Application
 
London, UK - 19 December 2019: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that an application has been made to the London Stock Exchange for a block listing of securities in respect of 1,500,000 ordinary shares of £0.01 each (the 'New Ordinary Shares') to be admitted to trading on AIM.
The New Ordinary Shares represent an increase on the Company's current Block Listing facility admitted on 02 July 2018 (the 'Block Listing'). It is expected that the admission of the New Ordinary Shares will become effective on 02 January 2020.
Ordinary Shares from the Block Listing will be issued from time to time in order to satisfy the exercise of share options granted under the Ergomed plc Long Term Incentive Plan.
When issued, the New Ordinary Shares will be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares of £0.01 each in the capital of the Company ('Ordinary Shares').
The Company will notify as required when there are changes to the issued share capital of the Company, and these figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
ENDS
Enquiries:



Ergomed plc


Tel: +44 (0) 1483 402 975




Richard Barfield (Chief Financial Officer)




























Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Freddie Barnfield/Huw Jeremy (Nominated Adviser)








James Black (Broker)




























Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Sue Stuart
Matthew Neal/Olivia Manser


ergomed@consilium-comms.com
























MC Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke







 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and clinical trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognized specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ALSKMMMZMLNGLZM